Muna Isaac-Escorcia
Muna Isaac-Escorcia has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Polo-Barranco
Faculty of Medicine, Universidad Metropolitana de Barranquilla, Barranquilla 080002, Colombia
4 shared publications - Carlos Rebolledo-Maldonado
Faculty of Medicine, Universidad Metropolitana de Barranquilla, Barranquilla 080002, Colombia
4 shared publications - Dairo Rodelo-Barrios
Department of Critical Medicine and Intensive Care, Faculty of Medicine, Simón Bolívar University, Barranquilla 080002, Colombia
4 shared publications - José Correa-Guerrero
Department of Critical Medicine and Intensive Care, University of Cartagena, Cartagena de Indias 130005, Colombia, Colombia
4 shared publications - Valentina Rada-Obeso
Faculty of Medicine, Universidad Metropolitana de Barranquilla, Barranquilla 080002, Colombia
4 shared publications - Elber Osorio-Rodríguez
Group Care Medicine, Department of Intensive Medicine, Clínica Colsanitas S.A., Clínica Iberoamérica, Barranquilla 080002, Colombia
3 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6639
Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved
Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD). Mechanistically, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcific remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, recruitment of cells of the monocytic lineage, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin–lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells toward myofibroblastic and/or osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence supports an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.
- 25 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6639
Open AccessRole of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved
Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD). Mechanistically, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcific remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, recruitment of cells of the monocytic lineage, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin–lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells toward myofibroblastic and/or osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence supports an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.
- Open Access
- 26 June 2026
- Published by MDPI AG in Preprints.org
Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved
Lipoprotein(a) [Lp(a)] is a predominantly genetic risk factor for atherosclerotic cardiovascular disease and calcified aortic valve disease (CAVD). In addition to its epidemiological and genetic association with aortic stenosis, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcifying remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, monocyte and macrophage recruitment, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells to myofibroblastic and osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence support an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.
- 26 June 2026
- Published by MDPI AG in Preprints.org
Open AccessRole of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved
Lipoprotein(a) [Lp(a)] is a predominantly genetic risk factor for atherosclerotic cardiovascular disease and calcified aortic valve disease (CAVD). In addition to its epidemiological and genetic association with aortic stenosis, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcifying remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, monocyte and macrophage recruitment, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells to myofibroblastic and osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence support an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.
- Open Access
- 26 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11427
Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Even when people with diabetes mellitus (DM) meet their cholesterol goals, they still face a higher risk of heart and blood vessel problems. One major reason is a particle called lipoprotein(a), or Lp(a), which is similar to LDL cholesterol. Raised levels of Lp(a) are inherited rather than caused by lifestyle. Lp(a) can build up in the body and make it easier for blood clots to form because it closely resembles a protein called plasminogen, reducing its ability to form plasmin that dissolves blood clots. At the same time, chemical changes like oxidation and glycation can make blood vessels more inflamed, adding to the risk. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast to RNA-based targeted agents (antisense oligonucleotides and siRNA [Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in Phase 2 clinical trials. In this review, we bring together findings from laboratory research and clinical studies, and highlight why it is important to measure Lp(a) levels—at least once in a person’s life, and especially in those with diabetes—to help doctors better assess risk and plan more effective treatments. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.
- 26 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11427
Open AccessDiabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Even when people with diabetes mellitus (DM) meet their cholesterol goals, they still face a higher risk of heart and blood vessel problems. One major reason is a particle called lipoprotein(a), or Lp(a), which is similar to LDL cholesterol. Raised levels of Lp(a) are inherited rather than caused by lifestyle. Lp(a) can build up in the body and make it easier for blood clots to form because it closely resembles a protein called plasminogen, reducing its ability to form plasmin that dissolves blood clots. At the same time, chemical changes like oxidation and glycation can make blood vessels more inflamed, adding to the risk. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast to RNA-based targeted agents (antisense oligonucleotides and siRNA [Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in Phase 2 clinical trials. In this review, we bring together findings from laboratory research and clinical studies, and highlight why it is important to measure Lp(a) levels—at least once in a person’s life, and especially in those with diabetes—to help doctors better assess risk and plan more effective treatments. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.
- Open Access
- 17 November 2025
- Published by MDPI AG in Preprints.org
Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Diabetes mellitus (DM) is associated with a residual cardiovascular risk that persists even when lipid targets are achieved. Within this context, lipoprotein(a) [Lp(a)], an LDL-like particle of genetic origin with pro-atherogenic and antifibrinolytic properties, emerges as a key determinant in the progression of both microvascular and macrovascular complications. Its structural homology with plasminogen promotes thrombosis, while oxidative and glycation modifications amplify endothelial inflammation. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast with RNA-based targeted agents (antisense oligonucleotides and siRNA[Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in phase 2 clinical trials. This review integrates molecular mechanisms and clinical evidence, emphasizing the need to incorporate Lp(a) quantification (at least once in a lifetime, and selectively in DM) to refine risk stratification and guide intensive interventions. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.
- 17 November 2025
- Published by MDPI AG in Preprints.org
Open AccessDiabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Diabetes mellitus (DM) is associated with a residual cardiovascular risk that persists even when lipid targets are achieved. Within this context, lipoprotein(a) [Lp(a)], an LDL-like particle of genetic origin with pro-atherogenic and antifibrinolytic properties, emerges as a key determinant in the progression of both microvascular and macrovascular complications. Its structural homology with plasminogen promotes thrombosis, while oxidative and glycation modifications amplify endothelial inflammation. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast with RNA-based targeted agents (antisense oligonucleotides and siRNA[Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in phase 2 clinical trials. This review integrates molecular mechanisms and clinical evidence, emphasizing the need to incorporate Lp(a) quantification (at least once in a lifetime, and selectively in DM) to refine risk stratification and guide intensive interventions. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.